Get started
Author

Sujun Gao

Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
2020 · Yuqin Song, Keshu Zhou, et al. · Clinical Cancer Research · 184
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
2022 · Yuqin Song, Keshu Zhou, et al. · Blood · 175
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
2020 · Wei Xu, Shenmiao Yang, et al. · Journal of Hematology & Oncology · 126
PDF
Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies
2018 · Cong Wang, Yan Yang, et al. · Critical Reviews in Oncology/Hematology · 95
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia
2021 · Heng Mei, Xiaofan Liu, et al. · Journal of Hematology & Oncology · 75
PDF
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
2023 · Yuqin Song, Luis Malpica, et al. · The Lancet Oncology · 70
TNF-α enhances Th9 cell differentiation and antitumor immunity via TNFR2-dependent pathways
2019 · Yuxue Jiang, Jintong Chen, et al. · Journal for ImmunoTherapy of Cancer · 64
PDF
An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low‐dose all‐trans retinoic acid
2004 · Guanjun Wang, Wei Li, et al. · Hematological Oncology · 64
Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions
2022 · Long Su, Yuan-Yuan Shi, et al. · Frontiers in Oncology · 51
PDF
Interleukin-33 Contributes to the Induction of Th9 Cells and Antitumor Efficacy by Dectin-1-Activated Dendritic Cells
2018 · Jintong Chen, Yinghua Zhao, et al. · Frontiers in Immunology · 50
PDF
Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significance
2018 · Long Su, YeHui Tan, et al. · Oncotarget · 49
PDF
Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia
2023 · Jingnan Sun, Ruiping Hu, et al. · International Journal of Biological Sciences · 42
PDF
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study
2023 · Wei Xu, Keshu Zhou, et al. · American Journal of Hematology · 39
PDF
Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study
2020 · Lixin Wang, Jianmin Luo, et al. · Clinical Epigenetics · 39
PDF
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor‐naive patients with PNH ( COMMODORE 3): A multicenter, Phase 3, single‐arm study
2023 · Hui Liu, Linghui Xia, et al. · American Journal of Hematology · 38
PDF
Asian Population Is More Prone to Develop High-Risk Myelodysplastic Syndrome, Concordantly with Their Propensity to Exhibit High-Risk Cytogenetic Aberrations
2021 · Yan Jiang, Jean-Richard Eveillard, et al. · Cancers · 38
PDF
CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations
2019 · Long Su, SuJun Gao, et al. · Annals of Hematology · 38
Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial
2018 · Yuqin Song, Keshu Zhou, et al. · Blood · 38
Interleukin-18 genetic polymorphisms contribute differentially to the susceptibility to Crohn’s disease
2015 · Su-Jun Gao · World Journal of Gastroenterology · 37
PDF
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials
2021 · Keshu Zhou, Dehui Zou, et al. · Journal of Hematology & Oncology · 35
PDF
IL-33 drives the antitumor effects of dendritic cells via the induction of Tc9 cells
2018 · Ning Liu, Yuxue Jiang, et al. · Cellular and Molecular Immunology · 35
A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy
2022 · Guangxin Peng, Guangsheng He, et al. · Therapeutic Advances in Hematology · 33
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
2023 · Li-Juan Deng, Ke-Shu Zhou, et al. · Blood Advances · 32
PDF
Genome-wide interaction target profiling reveals a novel Peblr20-eRNA activation pathway to control stem cell pluripotency
2019 · Cong Wang, Lin Jia, et al. · Theranostics · 32
PDF
ARNT / HIF ‐1β links high‐risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma
2018 · Chuan Wu, Ting Yang, et al. · Cancer Medicine · 32
PDF
Works count: 221
Citation count: 2,452
H-index: 27
I10-index: 60
Year
Topic
Type